

# Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase

Jung Min Choi<sup>a,1</sup>, Moon-Hyeong Seo<sup>a,1</sup>, Hyun-Ho Kyeong<sup>a</sup>, Eunkyung Kim<sup>a,2</sup>, and Hak-Sung Kim<sup>a,b,3</sup>

<sup>a</sup>Department of Biological Sciences and <sup>b</sup>Graduate School of Nanoscience and Technology, Korea Advanced Institute of Science and Technology, Daejeon 305-701, Korea

Edited\* by Stephen J. Benkovic, Pennsylvania State University, University Park, PA, and approved May 6, 2013 (received for review January 9, 2013)

**Glucokinase (GK) is a monomeric allosteric enzyme and plays a pivotal role in blood glucose homeostasis. GK is regulated by GK regulatory protein (GKRP), and indirectly by allosteric effectors of GKRP. Despite the critical roles of GK and GKRP, the molecular basis for the allosteric regulation mechanism of GK by GKRP remains unclear. We determined the crystal structure of *Xenopus* GK and GKRP complex in the presence of fructose-6-phosphate at 2.9 Å. GKRP binds to a super-open conformation of GK mainly through hydrophobic interaction, inhibiting the GK activity by locking a small domain of GK. We demonstrate the molecular mechanism for the modulation of GK activity by allosteric effectors of GKRP. Importantly, GKRP releases GK in a sigmoidal manner in response to glucose concentration by restricting a structural rearrangement of the GK small domain via a single ion pair. We find that GKRP acts as an allosteric switch for GK in blood glucose control by the liver.**

hexokinase | sigmoidicity | conformational restriction | type 2 diabetes

**G**lucokinase (GK), a hexokinase isozyme, is a monomeric allosteric enzyme and mainly expressed in hepatocytes and pancreatic  $\beta$ -cells (1, 2). Through its unique kinetic character, GK plays a central role in blood glucose homeostasis by converting glucose to glucose-6-phosphate (G6P), enhancing glycogen synthesis, in hepatocytes (3), and sensing glucose for insulin secretion in pancreatic  $\beta$ -cells (4). Defect and mutations in GK are directly associated with type 2 diabetes and maturity-onset diabetes of the young type 2 (5, 6). Thus, GK has been an important molecular target for studying blood glucose homeostasis and developing antidiabetes drugs (5, 7, 8). The crystal structure of human GK (hGK) revealed that GK undergoes a slow and energetically unfavorable structural rearrangement of the small domain in response to glucose during the transition from a super-open conformation into an open conformation (9). As a result, GK exhibits a sigmoidal activity curve with respect to glucose concentration as a monomeric allosteric enzyme (9).

Unlike pancreatic  $\beta$ -cells, blood glucose control by the hepatocytes is more complicated. Hepatocytes remove high amount of exogenous glucose after a meal in a fast and efficient manner (3). At the same time, hepatocytes also produce endogenous glucose to blood stream to maintain blood glucose level in a fasting state (3, 10). GK must be fully active for fast glucose clearance after a meal (3), whereas it should be turned off during a fasting state to prevent futile cycling of endogenous glucose to G6P (10). Therefore, GK in hepatocytes is presumed to be regulated in a different way from that in pancreatic  $\beta$ -cells. In hepatocytes, GK is regulated by GK regulatory protein (GKRP) that is located mainly in hepatocytes with an excess ratio to GK (11, 12). GKRP allosterically regulates the activity and subcellular localization of GK (13, 14). GKRP inhibits and sequesters GK into the nucleus of hepatocytes and releases GK into the cytoplasm in response to glucose concentration (13–15). GK is also indirectly regulated by allosteric effectors of GKRP, such as fructose-1-phosphate (F1P) and fructose-6-phosphate (F6P) (11, 16). F1P is derived from fructose and sorbitol in a meal, and F6P is an intermediate product of glycolysis (16). Recent studies have characterized the biophysical features regarding the interaction

between GK and GKRP and a modulation through the effectors (17, 18). Despite the intensive studies on GK and GKRP, the molecular basis for the allosteric regulation mechanism of GK by GKRP remains poorly understood because of the lack of structural information of the GK/GKRP complex.

Here, to demonstrate the molecular mechanism for the allosteric regulation of GK by GKRP and effectors, we determined the crystal structure of a *Xenopus laevis* GK and GKRP complex in the presence of F6P. Structural analysis of the complex and mutational studies with human GK and GKRP revealed that GKRP interacts with GK mainly through hydrophobic interaction and inhibits GK activity through a single ion pair between GKRP and the small domain of GK. We also show the molecular mechanism by which F1P and F6P modulate the activity of GK through molecular dynamics simulations and mutational analysis. Importantly, GKRP was revealed to release GK in a sigmoidal manner in response to glucose concentration by restricting a structural rearrangement of the GK small domain through a single ion pair, acting as an allosteric switch for GK.

## Results

**Determination of Crystal Structure of GK/GKRP Complex.** We determined the crystal structure of a *X. laevis* GK/GKRP (xGK/xGKRP) complex in the presence of F6P at 2.9 Å (Fig. 1A and Table S1). Our attempts to crystallize a hGK/human GKRP (hGKRP) complex have been unsuccessful. The crystals contain two xGK/xGKRP complexes in an asymmetric unit, and share 82% and 58% sequence identity with hGK and hGKRP, respectively (Fig. S1). The overall structure of the xGK/xGKRP complex reveals that xGKRP is bound to the super-open conformation of xGK (Fig. 1B), sharing an rmsd of 1.7 Å for 406 C $\alpha$  atoms for the super-open conformation of apo-hGK [Protein Data Bank (PDB) ID code 1V4T] with an approximately 11° rotation of a small domain of xGK toward a large domain (Fig. S2). The structure of xGKRP comprises two sugar isomerase (SIS) superfamily domains and a C-terminal extended all-helical motif (Fig. 1A). The sugar-isomerase domains show typical  $\alpha\beta$  folds as reported elsewhere (19, 20) (Fig. S3). We identified the electron density of F6P as a linear keto form, as previously suggested (16), in SIS domain 1, where SIS domain 2 and the C-terminal motif meet together (Fig. 1A and C). A stretch of four residues including Ser179, Ser258, Glu347, and Lys513 of xGKRP

Author contributions: J.M.C., M.-H.S., and H.-S.K. designed research; J.M.C., M.-H.S., and H.-H.K. performed research; E.K. contributed new reagents/analytic tools; J.M.C., M.-H.S., and H.-H.K. analyzed data; and J.M.C. and H.-S.K. wrote the paper.

The authors declare no conflict of interest.

\*This Direct Submission article had a prearranged editor.


Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, [www.pdb.org](http://www.pdb.org) (PDB ID code 3W0L).

<sup>1</sup>J.M.C. and M.-H.S. contributed equally to this work.

<sup>2</sup>Present address: Accugen Healthcare, Daejeon 305-811, Korea.

<sup>3</sup>To whom correspondence should be addressed. E-mail: [hskim76@kaist.ac.kr](mailto:hskim76@kaist.ac.kr).

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1300457110/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1300457110/-DCSupplemental).




**Fig. 1.** Overall structure of xGK/xGKRP complex. (A) Cartoon representation of the xGK/xGKRP complex. xGK is shown in blue (large domain) and cyan (small domain), and xGKRP is in orange (SIS domain 1), red (SIS domain 2), and pink [C-terminal all- $\alpha$ -helical motif (CTM)]. F6P is shown through a stick representation. (B) Cartoon representation of the xGK in xGK/xGKRP complex; as in A but rotated 90°. For clarity, xGKRP is faintly presented. (C) Close-up view of F6P binding site. Difference electron density contoured at  $1.5\sigma$  is shown at F6P (green, stick model), which was excluded from the phase calculation. Oxygen, nitrogen, and phosphate atoms are shown in red, blue, and cyan, respectively. The dotted lines indicate intermolecular hydrogen bonds between F6P and xGKRP.

participate in the binding of F6P through hydrogen bonding (Fig. 1C). A previous study on rat GKRP also revealed that Ser179 and Lys513 interact with F6P (21).

**Analysis of Interface Between GK and GKRP.** Based on the crystal structure of the xGK/xGKRP complex, we analyzed the interface between GK and GKRP. The xGK/xGKRP complex shows that a wedge-shaped structure is formed by two loops (L1 and L2), two helices ( $\alpha 8$  and  $\alpha 14$ ), and one strand ( $\beta 10$ ) in SIS domain 2 of xGKRP, anchoring to the allosteric cleft in the hinge region of xGK (Fig. 2A). The interface between xGK and xGKRP is predominantly hydrophobic, with a total burial area of  $1,913 \text{ \AA}^2$ . The edge of the wedge formed by two loops, L1 and L2, of xGKRP creates multiple van der Waals contacts with the

hydrophobic surface in the cleft formed by a strand (S1), loops L1 and L2 from the large domain, loop L3 from the small domain, and connecting region II of the xGK, generating major hydrophobic interactions (Fig. 2A). A hydrophobic surface is composed of Leu40, Lys49, Leu51, Pro52, Tyr54, Arg56, Lys136, Met231, Leu236, Val237, Glu238, and Met244 from the large domain, and Asp191, Val192, and Val193 from the small domain of xGK (Fig. 2A and B). This hydrophobic surface interacts with Ala440, Gly441, and Tyr443 of loop L1 and Pro461, Ile462, Leu463, and Phe464 of loop L2 in xGKRP (Fig. 2A and B). It is interesting to note that most of the hydrophobic surface of xGK is located in the large domain. To assess the importance and universality of the interactions in a GK/GKRP complex, we performed a mutational analysis for hGKRP.



**Fig. 2.** Interface of xGK/xGKRP complex. (A) Close-up view of the xGK/xGKRP interface. (Inset) Location of interface. The residues and secondary structures of the wedge in xGKRP (red) are shown to interact with the residues in the allosteric cleft of xGK (blue and cyan). The hydrophobic interface in the cleft of xGK is presented as a transparent surface. The dotted circle in red indicates the ion pair between xGKRP and xGK small domain. (B) Ligplot of the residues in the interface between xGK and xGKRP complex. The side chains of the small domain (cyan) and large domain (blue) of xGK and SIS domain 2 (red) of xGKRP are shown. The dotted circle is the same as in A. (C) Inhibition of hGK activity by various hGKRP mutants. The activity shows average and SDs from triplicate experiments.

We mutated Leu463 and Phe465 in hGKRP to Ala, which are equivalent to Ile462 and Phe464 in xGKRP and share approximately one fourth of the hydrophobic contacts ( $481 \text{ \AA}^2$ ). In gel filtration analysis, the resulting hGKRP<sup>L463A/F465A</sup> mutant did not form a complex with hGK (Fig. S4), which indicates that hydrophobic interactions are crucial for the binding of GKR to GK.

The interface is further stabilized by conserved two ion pairs and three hydrogen bonds showing a charge complementarity to the wedge of xGKRP (Fig. 2A and Fig. S5). Glu238 of loop L4 in the large domain and Arg179 of  $\alpha 4$  in the small domain of xGK form ion pairs with Arg300 and Asp412 of xGKRP, respectively (Fig. 2A and B). Ile462 of xGKRP makes backbone-to-backbone hydrogen bonds with Leu236 and Glu238 of loop L4 in xGK. Lys136 of L3 in xGK makes a hydrogen bond with a backbone carboxyl group of Leu463 in xGKRP (Fig. 2B). Mutation in Lys136 of xGK, which is equivalent to Lys143 in rat GK, was shown to decrease the inhibition exerted by GKR in the study of rat GK (22). It is noteworthy that a single ion pair is the main interaction between xGKRP and the small domain of xGK. The mutations of Arg301 (Arg300 in xGKRP) or Asp413 (Asp412 in xGKRP) in hGKRP to Ala display comparable binding affinities to hGK as WT hGKRP does (Table 1). However, interestingly, hGKRP<sup>D413A</sup> showed a significantly decreased inhibitory effect on hGK compared with WT hGKRP (Fig. 2C). This result indicates that GKR inhibits the GK activity mainly by a conformational restriction through its ion pair to the GK small domain.

**Molecular Mechanism for Release of GK from GKR.** Our structural analysis revealed that GKR binds to the super-open conformation of GK. During catalysis, however, GK is released from GKR upon glucose binding and undergoes a conformational change to an open conformation (9). To demonstrate how GK dissociates from GKR in response to glucose, we superimposed the xGK/xGKRP complex to the open conformation of hGK (PDB ID code 1V4S). The superimposition revealed that the ion pair of GKR to the small domain of GK is no longer available between GKR and an open conformation of GK (Fig. 3A). Moreover, Tyr62 and Arg156 of hGK sterically clash with Gly441 and Ile462 of xGKRP (Fig. 3A and B). These two residues are located at the edge of the wedge in xGKRP. Moreover, Ile462 (Leu463 in hGKRP) was shown to be particularly crucial for a hydrophobic interaction between GK and GKR through the analysis of the hGKRP<sup>L463A/F465A</sup> mutant (Fig. S4). Consequently, a structural rearrangement of the GK small domain gives rise to a dissociation of the complex. It is therefore likely that GK will be released from GKR in a sigmoidal manner in response to glucose concentration as its activity. It should also be noted that GKR-bound GK cannot catalyze the reaction as a result of a conformational restriction of the small domain, and thus only free GK exhibits its activity. Also, GK activator (GKA),


which is bound in an open conformation of hGK (9), is revealed to locate in a distant site from GKR binding site (Fig. S6). This result indicates that GKA dissociates GKR (7, 9, 17, 23) through a structural rearrangement of GK.

**Modulation Mechanism of GK by Allosteric Effectors of GKR.** It was reported that the allosteric effectors of GKR such as F1P and F6P bind GKR and alter the interaction between GK and GKR and eventually the GK activity (11, 14, 16). As xGKRP has been shown to be insensitive to the binding of F6P and F1P (24), we used hGKRP to investigate the molecular mechanism by which effectors of GKR modulate the GK activity. We first examined the activity of hGK at varying concentrations of F1P and F6P in the presence of hGKRP. As shown in Fig. 4A, F1P showed a more significant effect on the GK activity than F6P. Next, we performed molecular dynamics simulations by using the model structure of hGKRP in the presence and absence of F1P and F6P based on the xGKRP structure. Displacement of  $\alpha$ -carbons in SIS domain 2 and C-terminal motif was shown to occur upon the binding of F6P and F1P in the time course of simulations (Fig. S7). The superimposition of F1P-bound hGKRP onto the xGK/xGKRP complex revealed that the C-terminal of  $\alpha 10$  moves away from F1P as a result of a steric hindrance between His351 and the hydroxyl group of C6 in F1P (Fig. 4B and C). Consequently, the helices  $\alpha 11$  to  $\alpha 13$  and a  $\beta$ -sheet,  $\beta 6$  to  $\beta 10$ , of SIS domain 2 rotate outward from the core helix  $\alpha 14$  (Fig. 4B) and displace the L2 toward GK, causing a steric hindrance to the GK binding with Leu463 of hGKRP (Fig. 4D). As shown in the hGKRP<sup>L463A/F465A</sup> mutant, Leu463 is the key residue of hydrophobic interaction in the GK/GKR complex. Thus, F1P perturbs the binding of GK to GKR and disrupts the complex by altering hydrophobic interaction between GK and GKR. It is noteworthy that F1P is likely to be more efficient than glucose or GKA in releasing GK from GKR. Although F1P, glucose, and GKA bind to distant sites from the interface of the GK/GKR complex (9), F1P induces direct disruption of the interface to release GK from GKR, whereas glucose and GKA induce slow and energetically unfavorable rearrangement of the GK small domain (9, 17). The superimposition of F6P-bound hGKRP onto apo-hGKRP revealed that the interaction between the hydroxyl group of C1 in F6P and Glu348 of  $\alpha 10$  in SIS domain 2 shifts  $\alpha 10$  downward (Fig. S8A and B) and rotates the helices  $\alpha 11$  to  $\alpha 13$  and a  $\beta$ -sheet,  $\beta 6$  to  $\beta 10$ , of SIS domain 2 toward F6P (Fig. S8A), thereby moving L1 and L2 of the wedge close to  $\alpha 14$ , enhancing the binding of GK compared with apo-hGKRP (Fig. S8C). Thus, His351 and Glu348 are likely to be the key residues in the allosteric regulation of hGKRP by its effectors. To verify the modulation mechanism described earlier, we mutated Glu348 and His351 in hGKRP to Asp and Pro, respectively. The structural consistency between hGKRP<sup>E348A/H351P</sup> and WT hGKRP were confirmed based on CD analysis and binding of F6P to hGKRP<sup>E348A/H351P</sup> by isothermal titration calorimetry (ITC; Fig. S9 and Table S2). The binding affinity of hGKRP<sup>E348A/H351P</sup> for hGK measured by ITC was almost the same as WT apo-hGKRP regardless of the presence of F1P or F6P (Table 1). The inhibitory effect of hGKRP<sup>E348A/H351P</sup> on the hGK activity was comparable to hGKRP in the absence of F1P and F6P, and remained unchanged regardless of the presence of either (Fig. 4E). This result confirms the modulation mechanism of allosteric GKR by F1P and F6P and the key residues inducing the conformational changes in GKR. Furthermore, our result provided some insight into why hGKRP responds to the occupation of its allosteric site by F1P and F6P whereas xGKRP does not. Sequence alignment of various GKRs revealed that His351 of hGKRP is conserved in other species except xGKRP, which has Pro instead of His (Fig. S1). In addition, mutation of His351 to Pro resulted in no response of hGKRP to the binding of F1P and F6P as xGKRP. It is therefore likely that His351 of hGKRP has

**Table 1.**  $K_d$  values of hGK for WT hGKRP and its mutants in the presence and absence of F6P (200  $\mu\text{M}$ ) or F1P (100  $\mu\text{M}$ ) by ITC

Type	$K_d$ , nM
WT hGKRP	230 $\pm$ 26
WT hGKRP + F6P	95 $\pm$ 25
WT hGKRP + F1P	ND
hGKRP <sup>L463A/F465A</sup>	ND
hGKRP <sup>D413A</sup>	375 $\pm$ 97
hGKRP <sup>R301A</sup>	235 $\pm$ 34
hGKRP <sup>E348A/H351P</sup>	207 $\pm$ 27
hGKRP <sup>E348A/H351P</sup> + F6P	194 $\pm$ 21
hGKRP <sup>E348A/H351P</sup> + F1P	225 $\pm$ 50

ND, not determined.




**Fig. 3.** Structural changes of the interface in releasing GK from GKRP. (A) Close-up view of the xGK/xGKRP interface that superimposed onto open conformation of hGK. *Inset* represents the location of the interface. Superimposed open conformation of hGK (PDB ID code 1V45) onto the xGK/xGKRP complex is shown in blue (large domain) and dark cyan (small domain). GKA and glucose are indicated in stick model (purple). Orientation of the xGK small domain is shown in gray. Dotted arrow indicates the movement of Arg-179 of xGK (Arg-187 in hGK) during a structural rearrangement of the GK small domain. (B) Rotated (90°) close-up view of the *Inset* in A shows the surface of Arg-156 and Tyr-62 in hGK. Oxygen and nitrogen atoms are presented in red and blue, respectively. The color notation in xGKRP domains are the same as in Fig. 1.


a key role in the interaction with GK upon the binding of F6P and F1P to hGKRP, acting as a pivotal residue inducing the structural change of hGKRP. On the contrary, His-351, which plays a critical role in the interaction with GK, is not conserved in xGKRP, and consequently xGKRP does not respond to the occupation of its allosteric site by F1P and F6P.

**Implications for Physiological Role of GKRP.** GKRP is known to be located mainly in hepatocytes with an excess ratio to GK, regulating the allosteric GK in response to glucose concentration (12, 14, 15). To get some insight into the physiological implications for the role of GKRP, we attempted to investigate the regulatory features of GKRP. To this end, we first examined the dissociation of GK from GKRP in response to glucose, and determined the binding affinity of hGKRP and hGKRP<sup>D413A</sup> for hGK at varying glucose concentrations by using ITC (Fig. 5A and Fig. S10). As shown in Fig. 5A, the  $K_d$  of hGKRP for hGK displays a sigmoidal curve with respect to glucose concentration as presumed, showing an inflection point at approximately 20 mM

glucose. On the contrary, the binding affinity of hGKRP<sup>D413A</sup> for hGK greatly decreased even at 5 mM glucose. This result indicates that the ion pair between GKRP and the GK small domain is a key for generating a sigmoidal-type release of GK from GKRP in response to glucose concentration. To investigate the effect of GKRP on the kinetic behavior of GK, we measured the hGK activity with increasing ratios of hGKRP to hGK (Fig. 5B). The activity curve of hGK for a fourfold excess of hGKRP became more sigmoidal, resulting in a higher Hill coefficient (2.8) than with hGK alone (1.8; Table S3). The increased sigmoidicity of the GK activity curve is coincident with previous *in vivo* reports showing the free GK activity or detritiation of [2-<sup>3</sup>H] glucose of hepatocytes in response to glucose (25). Thus, the regulation of GK by GKRP in a sigmoidal pattern also seems to be valid *in vivo*. Interestingly, the hGK activity curve in the presence of hGKRP<sup>D413A</sup> or WT hGKRP and 25 mM KCl showed a decreased sigmoidicity compared with that with only WT hGKRP (Fig. 5C and Table S3). This result demonstrates that the increased sigmoidicity of the GK activity curve in the



**Fig. 4.** Modulation in the binding of GKRP to GK by allosteric effectors. (A) The activity of hGK measured at different concentrations of F1P and F6P in the presence of an equal molar ratio of hGKRP to hGK and 10 mM glucose. The activity indicates average and SDs from triplicate experiments. (B) Superimposition of F1P-bound hGKRP onto the xGK/xGKRP complex. The helices  $\alpha 11$  to  $\alpha 13$  and a  $\beta$ -sheet,  $\beta 6$  to  $\beta 10$ , of SIS domain 2 of hGKRP (green) and xGKRP (orange) are shown. xGK is represented in cyan. (C) Close-up view of the binding site for F1P and F6P. Stick representations of F1P (green) and F6P (orange) are shown. Residues from hGKRP (green) and xGKRP (orange) are also represented. (D) Rotated (90°) close-up view of the binding interface between GK and GKRP. L1 and L2 of hGKRP (green) and xGKRP (orange) are shown. The surface of Leu463 of hGKRP is shown. (E) Inhibition of hGK activity by hGKRP<sup>E348A/H351P</sup>. The hGK activity was determined with WT hGKRP or hGKRP<sup>E348A/H351P</sup> in the presence and absence of 0.1 mM F1P and 0.2 mM F6P. The activity represents average and SDs from triplicate experiments.



**Fig. 5.** Dissociation and kinetic behavior of GK in the presence of GKR and glucose. (A) Effect of glucose on the dissociation of hGK from hGKR. The  $K_d$  values of hGK for WT hGKR and hGKR<sup>D413A</sup> were determined by ITC at different glucose concentrations. (B) Activity of hGK determined with increasing the ratio of hGKR to hGK in response to glucose. (C) Activity of hGK determined at a fourfold excess of hGKR and hGKR<sup>D413A</sup> to hGK with respect to glucose. The hGK activity in the presence of 25 mM KCl and a fourfold excess of hGKR is also shown (□). The activity indicates average and SDs from triplicate experiments.

presence of GKR is attributed to the ion pair between GKR and the GK small domain. KCl seems to perturb the ion pair between GKR and the GK small domain. Thus, previous studies describing GKR as a classical competitive inhibitor (11, 26) are likely to be misled by addition of KCl. Our results imply that the release of GK from GKR in a sigmoidal manner in response to glucose concentration is crucial for blood glucose control by the liver.

## Discussion

We have demonstrated the molecular mechanism for the allosteric regulation of GK by GKR and effectors based on the structure of the GK/GKR complex. Our structural analysis revealed that GKR binds to a super-open conformation of GK mainly through hydrophobic interaction, inhibiting the GK activity by locking a small domain of GK. We also showed how allosteric effectors of GKR such as F1P and F6P indirectly modulate the GK activity in negative and positive way, respectively. More importantly, GKR was revealed to release GK in a sigmoidal manner in response to glucose concentration by restricting a structural rearrangement of the GK small domain via a single ion pair. This study elucidates the molecular mechanism by which an allosteric protein regulates a monomeric allosteric enzyme. The GK/GKR system exemplifies a unique case showing a cascade regulation mechanism of an allosteric enzyme by an allosteric regulatory protein and its effectors. Our results demonstrate the role for GKR as an allosteric switch (27) that turns GK “on” and “off” in response to glucose concentration, providing crucial insight into the understanding of blood glucose homeostasis and the development of new antidiabetes drugs.

The sigmoidal nature driven by GKR in regulating GK can be characterized into two distinct features. One is the release of GK from GKR in a sigmoidal manner with respect to glucose concentration, leading to an amplification of the GK activity at high glucose levels. The other is an increased sigmoidicity of the GK activity curve, resulting in a turning-off of GK at low glucose concentration. This sigmoidal feature results from the binding of GKR to a super-open conformation of GK and consequent restriction of a structural rearrangement of GK through a single ion pair. Those two features in regulation of GK by GKR seem to be essential for two major functions of the liver, glucose clearance and glucose production in blood glucose homeostasis (3, 10). As GK itself displays a sigmoidal activity curve with respect to glucose concentration (1, 3), a release of GK from GKR in a sigmoidal manner would significantly amplify the glucose clearance rate by the liver at high glucose levels. In addition, as free GK in cytosol can be degraded by proteasome after ubiquitination (28, 29), a sigmoidal-type release of GK by GKR can minimize the loss of GK within the low glucose levels. At low glucose concentration, GK remains turned off as a result of an increased sigmoidicity of the GK activity curve by GKR. Therefore, the production of glucose will be efficient because of

a blocking of fertile cycling of endogenous glucose to G6P (10) and maintenance of the cytosolic concentration of glucose at a higher level than in blood stream (5 mM) for facilitated diffusion of endogenous glucose by liver glucose transporter 2 (30). Thus, our results indicate that GKR acts as the allosteric switch that turns GK on and off in response to glucose concentration in blood glucose control by the liver.

The activity of hGK in the presence of hGKR at high glucose concentration is lower than expected, and this seems to be mainly caused by the difference in the conditions between in vitro and in vivo (Fig. S11). In the case of in vitro system, GK released from GKR by glucose can rebound to GKR, which results in a decreased GK activity. On the contrary, in vivo, released GK is translocated into the cytosol by its own nuclear exporting signal (31) and separated from GKR by nuclear membrane. Accordingly, translocated free GK exhibits its full activity in the cytosol, which is crucial for fast glucose clearance.

GK remains almost turned off in the range of 5 to 10 mM of glucose by the action of GKR (Fig. 5B). Thus, the negative effector such as F1P is likely to be essential for glucose clearance in this range of glucose. Accordingly, precursors of F1P, such as fructose or sorbitol (16), are likely to be important for glucose clearance by liver after a meal. Indeed, supply of fructose together with glucose was shown to increase glycogen synthesis by liver in the rat and dog (32, 33). Although fructose can be efficient to relieve hyperglycemia in diabetes, the use of fructose as a substituent for glucose for diabetes patients has raised the controversy (34, 35). F1P is effective for releasing GK from GKR, but a high amount or long-term supply of fructose might result in unexpected loss of GK as a result of proteasomal degradation of free GK in cytosol (29), which can cause the hyperglycemia to be more serious.

Allosteric activators of GK (i.e., GKAs) have been of great significance as antidiabetes drugs, and a number of diverse GKAs have been reported (5, 7–9). However, GKAs may cause serious side effects, as they change a sigmoidal activity curve of GK into a hyperbolic one (8, 9), and consequently alter the sensing of blood glucose level by GK in pancreatic  $\beta$ -cells, resulting in hyperinsulinemic hypoglycemia. As an approach to avoid the side effect, moderate or hepatocyte-specific GKAs are under development (36–38). With the same rationale and based on our result, GKR can be a target for the development of new antidiabetes drugs that activate GK in hepatocytes. As GKR is predominantly located in hepatocytes, the GKR-targeting drugs can activate GK specifically in hepatocytes, thus preventing possible hypoglycemia. The binding site of allosteric effectors in GKR and the interface of the GK/GKR complex can be most promising drug targets.

## Materials and Methods

The genes encoding GK and GKR from *X. laevis* and humans were expressed in *Escherichia coli* and purified by Ni affinity, anion exchange,

and gel-filtration chromatography. The crystals of *Xenopus* GK/GKRP complex were obtained by the hanging-drop vapor diffusion method, and the structure was solved by using the MR method. The binding affinities of GK for GKRP mutants were measured by ITC. The activities of GK in the presence and absence of GKRP and allosteric effectors were determined by a G6P dehydrogenase-coupled assay. Detailed materials and methods are described in *SI Materials and Methods*.

- Cornish-Bowden A, Cardenas ML (2004) Glucokinase: A monomeric enzyme with positive cooperativity. *Frontiers in Diabetes*, eds Matschinsky FM, Magnuson MA (Karger, Basel), Vol 16, pp 125–134.
- Iynedjian PB, Möbius G, Seitz HJ, Wollheim CB, Renold AE (1986) Tissue-specific expression of glucokinase: Identification of the gene product in liver and pancreatic islets. *Proc Natl Acad Sci USA* 83(7):1998–2001.
- Agius L (2008) Glucokinase and molecular aspects of liver glycogen metabolism. *Biochem J* 414(1):1–18.
- Matschinsky FM, et al. (1993) Glucokinase as pancreatic  $\beta$  cell glucose sensor and diabetes gene. *J Clin Invest* 92(5):2092–2098.
- Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. *Nat Rev Drug Discov* 8(5):399–416.
- Vionnet N, et al. (1992) Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. *Nature* 356(6371):721–722.
- Grimsby J, et al. (2003) Allosteric activators of glucokinase: Potential role in diabetes therapy. *Science* 301(5631):370–373.
- Matschinsky FM, et al. (2011) Research and development of glucokinase activators for diabetes therapy: Theoretical and practical aspects. *Handbook of Experimental Pharmacology*, eds Schwanstecher M (Springer, Berlin), Vol 203, pp 357–401.
- Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y (2004) Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. *Structure* 12(3):429–438.
- Nordlie RC, Foster JD, Lange AJ (1999) Regulation of glucose production by the liver. *Annu Rev Nutr* 19:379–406.
- Van Schaftingen E (1989) A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate. *Eur J Biochem* 179(1):179–184.
- Vandercammen A, Van Schaftingen E (1993) Species and tissue distribution of the regulatory protein of glucokinase. *Biochem J* 294(pt 2):551–556.
- Brown KS, Kalinowski SS, Megill JR, Durham SK, Mookhtiar KA (1997) Glucokinase regulatory protein may interact with glucokinase in the hepatocyte nucleus. *Diabetes* 46(2):179–186.
- de la Iglesia N, Veiga-da-Cunha M, Van Schaftingen E, Guinovart JJ, Ferrer JC (1999) Glucokinase regulatory protein is essential for the proper subcellular localisation of liver glucokinase. *FEBS Lett* 456(2):332–338.
- Toyoda Y, et al. (1994) Evidence for glucokinase translocation by glucose in rat hepatocytes. *Biochem Biophys Res Commun* 204(1):252–256.
- Detheux M, Vandercammen A, Van Schaftingen E (1991) Effectors of the regulatory protein acting on liver glucokinase: A kinetic investigation. *Eur J Biochem* 200(2):553–561.
- Futamura M, et al. (2006) An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. *J Biol Chem* 281(49):37668–37674.
- Anderka O, et al. (2008) Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: Impact of physiological and pharmacological effectors. *J Biol Chem* 283(46):31333–31340.
- Tepljakov A, Obmolova G, Badet-Denisot MA, Badet B, Polikarpov I (1998) Involvement of the C terminus in intramolecular nitrogen channeling in glucosamine 6-phosphate synthase: Evidence from a 1.6 Å crystal structure of the isomerase domain. *Structure* 6(8):1047–1055.
- Veiga-da-Cunha M, Sokolova T, Opperdoes FR, Van Schaftingen E (2009) Evolution of vertebrate glucokinase regulatory protein from a bacterial N-acetylmuramate 6-phosphate etherase. *Biochem J* 423(3):323–332.
- Veiga-da-Cunha M, Van Schaftingen E (2002) Identification of fructose 6-phosphate- and fructose 1-phosphate-binding residues in the regulatory protein of glucokinase. *J Biol Chem* 277(10):8466–8473.
- Veiga-da-Cunha M, Courtois S, Michel A, Gosselain E, Van Schaftingen E (1996) Amino acid conservation in animal glucokinases. Identification of residues implicated in the interaction with the regulatory protein. *J Biol Chem* 271(11):6292–6297.
- Zorn JA, Wells JA (2010) Turning enzymes ON with small molecules. *Nat Chem Biol* 6(3):179–188.
- Veiga-Da-Cunha M, Detheux M, Watelet N, Van Schaftingen E (1994) Cloning and expression of a *Xenopus* liver cDNA encoding a fructose-phosphate-insensitive regulatory protein of glucokinase. *Eur J Biochem* 225(1):43–51.
- Agius L (1998) The physiological role of glucokinase binding and translocation in hepatocytes. *Adv Enzyme Regul* 38:303–331.
- Vandercammen A, Van Schaftingen E (1991) Competitive inhibition of liver glucokinase by its regulatory protein. *Eur J Biochem* 200(2):545–551.
- Goodey NM, Benkovic SJ (2008) Allosteric regulation and catalysis emerge via a common route. *Nat Chem Biol* 4(8):474–482.
- Farrelly D, et al. (1999) Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: A sequestration mechanism in metabolic regulation. *Proc Natl Acad Sci USA* 96(25):14511–14516.
- Björkhaug L, Molnes J, Sovik O, Njølstad PR, Flatmark T (2007) Allosteric activation of human glucokinase by free polyubiquitin chains and its ubiquitin-dependent co-translational proteasomal degradation. *J Biol Chem* 282(31):22757–22764.
- Olson AL, Pessin JE (1996) Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. *Annu Rev Nutr* 16:235–256.
- Shiota C, Coffey J, Grimsby J, Grippo JF, Magnuson MA (1999) Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase. *J Biol Chem* 274(52):37125–37130.
- Boyd ME, Albright EB, Foster DW, McGarry JD (1981) In vitro reversal of the fasting state of liver metabolism in the rat. Reevaluation of the roles of insulin and glucose. *J Clin Invest* 68(1):142–152.
- Shiota M, et al. (2002) Inclusion of low amounts of fructose with an intraduodenal glucose load markedly reduces postprandial hyperglycemia and hyperinsulinemia in the conscious dog. *Diabetes* 51(2):469–478.
- Hallfrisch J, et al. (1983) Effects of dietary fructose on plasma glucose and hormone responses in normal and hyperinsulinemic men. *J Nutr* 113(9):1819–1826.
- Hawkins M, et al. (2002) Fructose improves the ability of hyperglycemia per se to regulate glucose production in type 2 diabetes. *Diabetes* 51(3):606–614.
- Pfefferkorn JA, et al. (2011) Designing glucokinase activators with reduced hypoglycemia risk: discovery of N, N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl) benzofuran-4-yloxy) pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus. *Med Chem Commun* 2:828–839.
- Bebernick GR, et al. (2009) Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. *J Med Chem* 52(19):6142–6152.
- Pfefferkorn JA, et al. (2012) Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. *J Med Chem* 55(3):1318–1333.